Cargando…
Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence
Hepatitis B virus (HBV) infection is a global health concern, and it is considered one of the deadliest infections in the world, having nearly 1.2 million deaths annually. Around 75% of all global HBV carriers live in the Asia-Pacific region. In this regard, India has a prevalence ranging between 2%...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117886/ https://www.ncbi.nlm.nih.gov/pubmed/34035566 http://dx.doi.org/10.4103/ijcm.IJCM_439_19 |
_version_ | 1783691651039887360 |
---|---|
author | Bhattacharya, Sudip Gökdemir, Özden Bashar, Md Abu Thiyagarajan, Arulmani Singh, Amarjeet |
author_facet | Bhattacharya, Sudip Gökdemir, Özden Bashar, Md Abu Thiyagarajan, Arulmani Singh, Amarjeet |
author_sort | Bhattacharya, Sudip |
collection | PubMed |
description | Hepatitis B virus (HBV) infection is a global health concern, and it is considered one of the deadliest infections in the world, having nearly 1.2 million deaths annually. Around 75% of all global HBV carriers live in the Asia-Pacific region. In this regard, India has a prevalence ranging between 2% and 7% with exposure rates of 10%–60%. Hepatitis B is a vaccine-preventable disease. In India, the World Health Organization protocol for hepatitis B vaccination has been followed, and it is given free of cost in public health facilities under the National Immunization Schedule. Despite the free hepatitis vaccination program in India, coverage and awareness are low. Low awareness, followed by low coverage of hepatitis vaccination, can prove dangerous for the Indian population in the long run. A majority of chronic hepatitis cases progress silently to end-stage liver disease without having many signs and symptoms. Once occurred, a complete cure is not possible with currently available drugs. The studies from neighboring countries such as China and Taiwan documented that the impact of single-dose booster for children of 10 years has made a significant difference from the cost-effectiveness perspective. They have also included the booster dose in their national vaccination program. Considering the low level of vaccination awareness, small coverage, high disease burden, and high treatment cost, now, it is high time for India to introduce hepatitis B booster vaccine. |
format | Online Article Text |
id | pubmed-8117886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-81178862021-05-24 Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence Bhattacharya, Sudip Gökdemir, Özden Bashar, Md Abu Thiyagarajan, Arulmani Singh, Amarjeet Indian J Community Med View Point Hepatitis B virus (HBV) infection is a global health concern, and it is considered one of the deadliest infections in the world, having nearly 1.2 million deaths annually. Around 75% of all global HBV carriers live in the Asia-Pacific region. In this regard, India has a prevalence ranging between 2% and 7% with exposure rates of 10%–60%. Hepatitis B is a vaccine-preventable disease. In India, the World Health Organization protocol for hepatitis B vaccination has been followed, and it is given free of cost in public health facilities under the National Immunization Schedule. Despite the free hepatitis vaccination program in India, coverage and awareness are low. Low awareness, followed by low coverage of hepatitis vaccination, can prove dangerous for the Indian population in the long run. A majority of chronic hepatitis cases progress silently to end-stage liver disease without having many signs and symptoms. Once occurred, a complete cure is not possible with currently available drugs. The studies from neighboring countries such as China and Taiwan documented that the impact of single-dose booster for children of 10 years has made a significant difference from the cost-effectiveness perspective. They have also included the booster dose in their national vaccination program. Considering the low level of vaccination awareness, small coverage, high disease burden, and high treatment cost, now, it is high time for India to introduce hepatitis B booster vaccine. Wolters Kluwer - Medknow 2021 2021-03-01 /pmc/articles/PMC8117886/ /pubmed/34035566 http://dx.doi.org/10.4103/ijcm.IJCM_439_19 Text en Copyright: © 2021 Indian Journal of Community Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | View Point Bhattacharya, Sudip Gökdemir, Özden Bashar, Md Abu Thiyagarajan, Arulmani Singh, Amarjeet Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence |
title | Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence |
title_full | Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence |
title_fullStr | Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence |
title_full_unstemmed | Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence |
title_short | Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence |
title_sort | is it the right time to introduce the hepatitis b booster vaccine in national immunization schedule? an analysis from the available evidence |
topic | View Point |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117886/ https://www.ncbi.nlm.nih.gov/pubmed/34035566 http://dx.doi.org/10.4103/ijcm.IJCM_439_19 |
work_keys_str_mv | AT bhattacharyasudip isittherighttimetointroducethehepatitisbboostervaccineinnationalimmunizationscheduleananalysisfromtheavailableevidence AT gokdemirozden isittherighttimetointroducethehepatitisbboostervaccineinnationalimmunizationscheduleananalysisfromtheavailableevidence AT basharmdabu isittherighttimetointroducethehepatitisbboostervaccineinnationalimmunizationscheduleananalysisfromtheavailableevidence AT thiyagarajanarulmani isittherighttimetointroducethehepatitisbboostervaccineinnationalimmunizationscheduleananalysisfromtheavailableevidence AT singhamarjeet isittherighttimetointroducethehepatitisbboostervaccineinnationalimmunizationscheduleananalysisfromtheavailableevidence |